- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: September 2025
- Public Summary Document (PSD) September 2025 PBAC Meeting - (PDF 520KB)
- Public Summary Document (PSD) September 2025 PBAC Meeting - (Word 129KB)
Osimertinib – September 2025
Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso®
Last updated
24 December 2025